Authored by Karl Simpson
Seattle Genetics are really blazing a trail in the area of antibody drug development, in particular, the antibody drug conjugate technology (ADC). The company was the first to get an ADC drug approved with ADCETRIS. Now, Seattle Genetics is looking to new therapeutic indications for the product and the presented data at ASCO outlining this. The company is conducting ongoing clinical trials in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL). The phase I trials are evaluating ADCETRIS for the frontline treatment of HL and MTCL, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphoma.
Seattle Genetics are a true technology pioneer in the antibody drug conjugates approach to delivering novel therapeutics for cancer. ADCs really target the cancer cells by delivering highly targeted antibodies.
ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtube disrupting agent, monomethyl auristatin E (MMAE), utilising Seattle’s proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumour cells.